Therapeutic monoclonal antibodies in human breast milk: a case study.
Recently, therapeutic monoclonal antibodies have been introduced for the treatment of advanced melanoma and other diseases. It remains unclear whether these drugs can be safely administered to women who are breast feeding because of the potential hazardous side effects for nursing infants. One such therapy for metastatic melanoma is ipilimumab, a human monoclonal antibody that blocks cytotoxic T-lymphocyte-antigen-4, and is the preferred treatment for patients with metastatic melanoma when other molecular therapies are not viable. This study measured ipilimumab levels in the breast milk of a patient undergoing treatment that were enough to raise concerns for a nursing infant exposed to ipilimumab.
Melanoma Research Program, School of Medicine, Division of Medical Oncology, Anschutz Medical Campus, University of Colorado, Aurora, Colorado, USA.
Elle
E
Ross
Steven E
SE
Robinson
Carol
C
Amato
Colette
C
McMillan
Jay
J
Westcott
Tiffany
T
Wolf
William A
WA
Robinson
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008895:Milk, Human / Q000378:metabolism*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000911:Antibodies, Monoclonal